# A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

> **NCT00379639** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 36 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00379639
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-01
- **Primary completion:** 2008-07-01
- **Final completion:** 2008-07-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379639, "A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00379639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*